Latest SEC Filings

Roivant Sciences Ltd.Roivant Sciences Reports $290.6 Million Net Loss and Decreased Revenue for Q2 2026

Scholar Rock Holding CorpScholar Rock Reports Q2 2026 Financial Results with $109.9M Net Loss

Unity Software Inc.Unity Software Inc. Reports 24% Revenue Growth to $546.5 Million in Q2 2026

REGENXBIO Inc.REGENXBIO Reports $108M Revenue and $22.7M Net Income in Latest Quarter

Sionna Therapeutics, Inc.Sionna Therapeutics Reports $56.7 Million Net Loss and Advances Clinical Trials

PRECISION BIOSCIENCES INCPrecision BioSciences Reports $51.1 Million Net Loss and No Revenue in Q2 2026

TIC Solutions, Inc.TIC Solutions Reports 86% Revenue Growth to $584.3 Million, Despite Net Loss in Latest Quarter

Cullinan Therapeutics, Inc.Cullinan Therapeutics Reports $53.7 Million Net Loss in Q2 2026, Decreased from Previous Year

Commerce.com, Inc.Commerce.com Reports Revenue Increase and Return to Profitability in Q2 2026

Vistance Networks, Inc.Vistance Networks Reports Q2 2026 Financial Results with $295.2M Net Income

Monte Rosa Therapeutics, Inc.Monte Rosa Therapeutics Reports 61% Decline in Collaboration Revenue for Q2 2026

Korro Bio, Inc.Korro Bio Reports $18.9 Million Net Loss in Q2 2026, Sees Decrease in Operating Expenses

OPEN TEXT CORPOpenText Corporation Reports $5.25 Billion Revenue for Fiscal Year 2026, 1.5% Increase

Core Natural Resources, Inc.Core Natural Resources Reports Revenue Growth and Net Income Turnaround Following Arch Resources Merger

Cartesian Therapeutics, Inc.Cartesian Therapeutics Reports Q2 2026 Financial Results with $15.8M Net Income

TripAdvisor, Inc.TripAdvisor Reports 7% Revenue Decline and Net Loss in Q2 2026

CPI Card Group Inc.CPI Card Group Reports 15% Revenue Growth to $149.2 Million in Q2 2026

Immunocore Holdings plcImmunocore Reports 18.3% Revenue Growth to $115.9 Million in Q2 2026

PAPA JOHNS INTERNATIONAL INCPapa John’s Reports 8.8% Revenue Decline in Q2 2026 Amid Operational Changes

Amylyx Pharmaceuticals, Inc.Amylyx Pharmaceuticals Reports $43.4 Million Net Loss in Q2 2026

Avalo Therapeutics, Inc.Avalo Therapeutics Reports $36.4 Million Net Loss in Q2 2026, Driven by Increased R&D Expenses

Kenvue Inc.Kenvue Inc. Reports $456 Million Net Income and $3.955 Billion Revenue for Q2 2026

Foghorn Therapeutics Inc.Foghorn Therapeutics Reports Increased Collaboration Revenue and Reduced Operating Losses in Q2 2026

STARWOOD PROPERTY TRUST, INC.Starwood Property Trust Reports 15.6% Revenue Growth but Decline in Net Income for Q2 2026

Unusual Machines, Inc.Unusual Machines Reports 687% Revenue Growth to $16.7 Million in Q2 2026